GCC nephrologists biopsy fewer than 30% of eligible proteinuric patients, versus roughly 70% in Japan and Germany, masking IgAN.

IgA nephropathy is estimated to affect 8,000 to 12,000 patients across the GCC, but the true IgAN fraction of incident CKD is difficult to establish. Most proteinuric patients in the region are attributed to diabetic nephropathy, reflecting the GCC's 35% to 40% adult diabetes prevalence, without a confirmatory kidney biopsy. KDIGO guidance calls for biopsy in non-diabetic proteinuria, yet a GCC nephrology network capacity survey finds biopsy performed in fewer than 30% of eligible proteinuric patients, versus roughly 70% in Japan and Germany. Under-biopsy is functionally equivalent to under-diagnosis: a patient never biopsied cannot be coded as IgAN.

Once diagnosed, GCC IgAN patients progress to end-stage renal disease 15% to 20% faster than European observational cohorts, consistent with later diagnosis, poorly controlled hypertension (mean systolic blood pressure at diagnosis of 148mmHg versus a sub-130mmHg target), and late initiation of ACE inhibitor or ARB therapy. Kidney biopsy capability is concentrated at fewer than 20 GCC centres with dedicated nephrology and interventional radiology teams; the patient journey from proteinuria detection to diagnosis typically takes 12 to 24 months, roughly double the 6 to 12 month European benchmark. GCC patients reaching ESRD represent a meaningful share of the region's dialysis population, with IgAN contributing an estimated 12% to 15%.

Diabetes is absorbing a kidney disease population that biopsy would reveal.

Five questions this report answers:

Q1 - How large is the true GCC IgAN population once corrected for diabetes misattribution?

Q2 - Which GCC nephrology centres have kidney biopsy capacity, and how does that gate access to novel therapy?

Q3 - What does ACEi/ARB-first standard of care mean for budesonide and sparsentan entry?

Q4 - What diagnostic and access barriers define the addressable GCC IgA nephropathy market?

Q5 - Why do GCC IgAN patients reach ESRD 15-20% faster than European cohorts?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#IgANephropathy #Nephrology #RareDisease #GCCHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/iga-nephropathy/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/